U.S. markets closed
  • S&P 500

    4,185.47
    +15.05 (+0.36%)
     
  • Dow 30

    34,200.67
    +164.68 (+0.48%)
     
  • Nasdaq

    14,052.34
    +13.58 (+0.10%)
     
  • Russell 2000

    2,262.67
    +5.60 (+0.25%)
     
  • Crude Oil

    63.07
    -0.39 (-0.61%)
     
  • Gold

    1,777.30
    +10.50 (+0.59%)
     
  • Silver

    26.04
    +0.08 (+0.29%)
     
  • EUR/USD

    1.1980
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • GBP/USD

    1.3840
    +0.0056 (+0.41%)
     
  • USD/JPY

    108.7830
    +0.0670 (+0.06%)
     
  • BTC-USD

    61,076.61
    -719.41 (-1.16%)
     
  • CMC Crypto 200

    1,398.97
    +7.26 (+0.52%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,683.37
    +40.68 (+0.14%)
     

Respinova Granted FDA 510(k) Clearance for Pulsehaler™

·1 min read

HERZLIYA, Israel, April 6, 2021 /PRNewswire/ -- Respinova Ltd. is pleased to announce it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Pulsehaler™. Pulsehaler™ is an innovative device that facilitates the opening of airways and clearance of secretions in patients with respiratory diseases.

"Despite the available pharma treatments, patients with COPD, Asthma, CF and other respiratory diseases unfortunately still suffer from poor quality of life," commented Professor Raphael Breuer, MD, former Head of the Institute of Pulmonology at Hadassah University Medical Center. "Pulsehaler™ brings a novel approach that will help patients with these conditions open their airways, which should improve their symptoms significantly", he added.

"This FDA clearance for Pulsehaler™ is an important milestone for the company," said Cliff Ansel, CEO of Respinova Ltd. "We are excited to bring this innovative technology to respiratory patients".

Pulsehaler™ is the first device to use patented Dynamic Multi-frequency Pressure Pulse™ technology. Driven by an internal turbine and multi-frequency vibration disc, Pulsehaler™ sends air pressure pulsations directly into the lung, making it easier to use for patients with airway restrictions.

About Respinova Ltd.:

Respinova is a privately held medical technology company based in Herzliya, Israel. Our team has decades of experience in developing and commercializing innovative medical devices in diverse therapeutic areas. Respinova is a two-time winner of the prestigious European Horizon program (Horizon 2020 SME and Horizon EIC).

Contact:

Cliff Ansel, CEO
cliff@respinova.com
www.respinova.com

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/respinova-granted-fda-510k-clearance-for-pulsehaler-301263037.html

SOURCE Respinova Ltd.